Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary Endpoint

뉴스 본문을 불러오고 있어요.

Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary Endpoint | 웨이프 WAPE

Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary Endpoint

기사 요약

관련 종목

댓글 —